Compare Citius Pharmaceuticals Inc (CTXR) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 2092.5× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 37,320,110). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| CTXR | LQD | |
|---|---|---|
Market Cap | $13.62M | $28.50B |
Volume | 132,438 | 37,320,110 |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $112.91 |
52-Week Low | $0.48 | $101.83 |
Typical Hold Time | 17 Days | 125 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
LQD trades at $102.47 with a slight 0.34% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September 2026 and concerns about rising Treasury yields impacting investment-grade corporate bonds.
The outlook remains cautious as rising interest rates pressure bond ETFs, though LQD's 4.8% yield and high-quality portfolio provide some stability. Key risks include further bond market volatility and economic uncertainty, while institutional activity shows mixed sentiment with elevated short positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
